Champions Oncology Inc Asset Resilience Ratio
Champions Oncology Inc asset resilience ratio. Champions Oncology Inc (CSBR) has an Asset Resilience Ratio of 0.00% as of October 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CSBR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Champions Oncology Inc (2009–2018)
Asset resilience ratio of Champions Oncology Inc from 2009 to 2018. This chart shows how Champions Oncology Inc's Asset Resilience Ratio has changed over time. Read Champions Oncology Inc (CSBR) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Champions Oncology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Champions Oncology Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Champions Oncology Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Champions Oncology Inc Industry Peers by Asset Resilience Ratio
Compare Champions Oncology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Champions Oncology Inc Asset Resilience Ratio by Year (2009–2018)
Champions Oncology Inc asset resilience ratio by year from 2009 to 2018. The table below shows the annual Asset Resilience Ratio data for Champions Oncology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-04-30 | 0.00% | $0.00 | $8.08 Million | -- |
| 2017-04-30 | 0.00% | $0.00 | $8.01 Million | -- |
| 2016-04-30 | 0.00% | $0.00 | $5.78 Million | -- |
| 2015-04-30 | 0.00% | $0.00 | $12.05 Million | -- |
| 2014-04-30 | 0.00% | $0.00 | $8.87 Million | -- |
| 2013-04-30 | 0.00% | $0.00 | $11.69 Million | -- |
| 2012-04-30 | 0.00% | $0.00 | $6.92 Million | -- |
| 2009-04-30 | 22.01% | $1.02 Million | $4.62 Million | -- |
About Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform … Read more